Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportPoster - PhysicianPharm

I-123-ioflupane quantification in Lewy Body Dementia and Parkinson Disease using xSPECT-derived absolute and relative SUV: an updated analysis

Mario Jreige, Gilles Allenbach, MARIE MEYER, Marie Nicod-Lalonde, Niklaus Schaefer, David Benninger and John Prior
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1069;
Mario Jreige
1Lausanne University Hospital Lausanne Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilles Allenbach
2Chuv Epalinges Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIE MEYER
3CHUV Lausanne Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Nicod-Lalonde
3CHUV Lausanne Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Niklaus Schaefer
3CHUV Lausanne Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Benninger
1Lausanne University Hospital Lausanne Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Prior
4Lausanne University Hospital La Conversion Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1069

Aim: Quantification of I-123-Ioflupane uptake within basal ganglia using the latest SPECT scanners may add valuable accuracy to diagnosis of nigrostriatal pathway pathologies. We investigated the validity of absolute and relative SUV quantification of I-123-Ioflupane compared to the conventional visual rating in differentiating between normal and pathologic scans in patients investigated for either presumed Lewy Body Dementia (LBD) or Parkinson Disease (PD). Materials and Methods: Hundred eleven individuals (PD, n=79; LBD, n=32) were scanned (Symbia Intevo, Siemens Healthineers) and images reconstructed using conventional iterative reconstruction (Flash 3D) and quantitative xSPECT reconstruction providing SUV values. Data were analyzed using Scenium (Siemens Healthineers) by a co-registration of the individual tomographic data to a reference template followed by the application of a standard set of volumes of interest (VOI) and fully-automated extraction of mean regional counts and SUV values for the left and right caudate nucleus, putamen and striatum, as well as for the occipital region, taken as reference region for the calculation of relative SUV (rSUV). We compared SUVmean, SUVmax and rSUV in normal and abnormal subgroups for each region of interest and between both groups.

Results: Based on visual rating and relative metric methods, 48/79 (61%) with presumed PD and 14/32 (43%) with LBD scans were scored as abnormal.Absolute SUVmax and rSUV allowed differentiating between normal and pathological DATscan in the caudate nucleus (p<0.005 and p=0.01), putamen (p<0.005 and p<0.005) and striatum (p<0.005 and p<0.005) in PD subgroup and in the putamen (p<0.005 and p<0.005) in LBD subgroup. Absolute SUVmax allowed differentiating between normal and pathological DATscan in the striatum (p<0.005) and rSUV in the caudate nucleus (p<0.005) in LBD subgroup. SUVmean allowed to differentiate between normal and pathological cases in the striatum (PD: p<0.005, LBD: p<0.005), putamen (PD: p<0.005, LBD: p<0.005) and caudate nucleus (PD: p<0.005, LBD: p=0.006) for both PD and LBD subgroups.Only caudate nucleus SUVmean and rSUV showed significantly lower values in pathologic LBD compared to PD subgroup.

Conclusions: Quantification of I-123-ioflupane uptake using xSPECT-derived allows differentiating between normal and pathological DATscan in PD and LBD. This has the potential to increase diagnostic accuracy by eliminating background noise bias, as well as increasing DATscan specificity.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
I-123-ioflupane quantification in Lewy Body Dementia and Parkinson Disease using xSPECT-derived absolute and relative SUV: an updated analysis
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
I-123-ioflupane quantification in Lewy Body Dementia and Parkinson Disease using xSPECT-derived absolute and relative SUV: an updated analysis
Mario Jreige, Gilles Allenbach, MARIE MEYER, Marie Nicod-Lalonde, Niklaus Schaefer, David Benninger, John Prior
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1069;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
I-123-ioflupane quantification in Lewy Body Dementia and Parkinson Disease using xSPECT-derived absolute and relative SUV: an updated analysis
Mario Jreige, Gilles Allenbach, MARIE MEYER, Marie Nicod-Lalonde, Niklaus Schaefer, David Benninger, John Prior
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1069;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Poster - PhysicianPharm

  • Preliminary result of Texture Analysis on prediction of overall outcome of neuroendocrine tumors based on pre-therapy heterogeneity of somatostatin receptors on 68Ga Dotatate PET/CT scans.
  • Comparison of regadenoson and dypiridamole myocardial blood flow and coronary flow reserve hyperemic response by non-invasive quantitative N-13 ammonia PET.
  • 177Lu-PSMA-617 versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer: a randomised, open-label, phase 2 trial (TheraP)
Show more Poster - PhysicianPharm

Neurology and Psychiatry

  • Sex modifies the APOE e4 dose dependent effect on brain region-specific tau deposition measured by 18F-flortaucipir PET in individuals with cognitive impairment
  • Semiquantitative Approach to Amyloid PET Interpretation in Clinical Practice
  • Monkey, rat, and first in human evaluation of [18F]PF-06445974, a PET radioligand that preferentially labels phosphodiesterase 4B
Show more Neurology and Psychiatry

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire